Bulk order Acrobiosystems for Chinese

Chinese

A-Z

Trimer | Siglec-15 | CD20 | FGL1 | CD19 | PD-1

There is no goods in the shopping cart !

My Cart

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

Home
Product & Service

Products by Category

Recombinant proteins and more
Immune Checkpoint ProteinsHot Targets of CAR-T Cell TherapyNew Biosimilar Drug TargetsHot Anti-idiotypic AntibodyHot Fc Receptor Proteins Llama IgG Fc Fusion ProteinNew Bio-Markers & CD Antigens ActiveMax -Best Cytokines Viral Proteins Enzymes Antibodies All Recombinant Proteins
Services

Innovation Lab ServicesNew

Pre-labeled proteins
Biotinylated protein collectionHot FITC & PE labeled ProteinsNew Fluorescent fusion proteins
Kits
ELISA Assay Kits for Quantitative Analysis of Therapeutic Antibodies in Serum SamplesNew Inhibitor Screening Kits Five-Minute MAB Isotyping Kits
Others
HPLC-verified Proteins

Hot Products

mAb for Anti-CD20 CAR Detection - Flow Cytometry ValidatedNew Siglec-15 - Validated by Cell-based Assay BLI/ SPR/ ELISANew Integrin - Integrin ProteinsNew CD20 - Full Length ProteinExclusive FGL1 - Fibrinogen-like protein 1New PD1 - PD1 Pathway TargetsHot CD19 - High Affinity CD19, Designed for Detection of Anti-CD19 CAR ExpressionNew CD3E - Biotinylated CD3E productsHot BCMA - B-Cell Maturation Antigen TIGIT - TIGIT Signaling Axis CD47 - Leukocyte Surface Antigen CD47 LAG3 - Lymphocyte-activation gene 3 ROR - Recombinant ROR1 & ROR2
Support

How to Order Shipping & Payments Global Distributors Testimonials Download Brochures Download COA
Application

Quantitative Analysis of mAb in Serum Evaluation of CAR Expression
X-LAB
Company

About Us Join Us Contact Us
Activity

News Exhibitions Promotion

Your Position: Home > All Other Proteins > BCMA > BCA-H5253

Human BCMA / TNFRSF17 Protein, Mouse IgG2a Fc Tag, low endotoxin

INTRODUCTION

QC & Assay Protocol

Citation & Background

Synonym
TNFRSF17,CD269,BCM,BCMA
Source
Human BCMA, Mouse IgG2a Fc Tag, low endotoxin (BCA-H5253) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ala 54 (Accession # Q02223-1).
Predicted N-terminus: Met 1
Request for sequence
Molecular Characterization
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 32.8 kDa. The protein migrates as 35-42 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.1 EU per μg by the LAL method.
Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20^°C to -70^°C for 12 months in lyophilized state;
2. -70^°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE

Human BCMA, Mouse IgG2a Fc Tag, low endotoxin on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity-ELISA

Human BCMA, Mouse IgG2a Fc Tag, low endotoxinHuman BCMA, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. BCA-H5253) ELISA bioactivity

Immobilized Human BAFF, Fc Tag (Cat. No. BAF-H4268) at 2 μg/mL (100 μL/well) can bind Human BCMA, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. BCA-H5253) with a linear range of 0.2-0.8 ng/mL (QC tested).

Protocol

Immobilized Human BCMA, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. BCA-H5253) at 2 μg/mL (100 μL/well) can bind Anti-Human BCMA Mab with a linear range of 0.2-3 ng/mL (Routinely tested).

Protocol

Immobilized Human APRIL, Fc Tag (Cat. No. APL-H5267) at 5 μg/mL (100 μL/well) can bind Human BCMA, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. BCA-H5253) with a linear range of 0.2-2 ng/mL (Routinely tested).

Protocol

Background
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.
References
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Order Details

BCA-H5253-100ug

Price(USD) : $350.00

BCA-H5253-1mg (500ug × 2)

Price(USD) : $2310.00

Add to Cart

Bulk Inquiry Customize Product

Promotion & Exhibitions

Fluorescence Labeled CAR-T Target Proteins

PEGS Boston 2019
PepTalk 2019

Drug Development Status

Number of Launched Drugs：0 Details
Number of Drugs in Clinical Trials：28 Details
Latest Research Phase：Phase ?

More Recommended Products

Datasheet & Documentation

Contact Us

order@acrobiosystems.com

techsupport@acrobiosystems.com

+1 800-810-0816 (US)

+86 400-682-2521 (AP)

Show All Distributors

New Product Launch

Questions & Comments

English Name	Research Code	Research Phase	Company	Indications	Clinical Trials
TNB-383B	TNB-383B	Phase Ⅰ	Teneobio, Abbvie	Multiple myeloma (MM)	Details
LCAR-B38M cell product	JNJ-4528; JNJ-68284528; LCAR-B38M, JNJ 4528	Phase Ⅲ	Nanjing Chuanqi Biotech, Janssen	Multiple myeloma (MM)	Details
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology)		Phase Ⅰ	Wuhan Union Hospital, Shengyan Pharmaceutical Technology	Multiple myeloma (MM)	Details
BCMA-CART (PD-1 knockdown, Unicar-Therapy Bio-medicine Technology)		IND Filing	Unicar-Therapy Bio-medicine Technology	Multiple myeloma (MM)	Details
Belantamab mafodotin	GSK-2857916	Phase Ⅲ	GlaxoSmithKline	Multiple myeloma (MM)	Details
Idecabtagene vicleucel	bb-2121	Phase Ⅲ	bluebird bio, Celgene	Multiple myeloma (MM)	Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army)		Phase Ⅱ	General Hospital of the People's Liberation Army	Multiple myeloma (MM)	Details
CART-BCMA	CART-BCMA; MTV-273,CART BCMA,MTV273	Phase Ⅰ	University of Pennsylvania, Novartis	Multiple myeloma (MM)	Details
P-BCMA-101	P-BCMA-101	Phase Ⅱ	Poseida Therapeutics	Multiple myeloma (MM)	Details
BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group)		Phase Ⅱ	Asclepius Technology Company Group	Multiple myeloma (MM)	Details
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics)		Phase Ⅰ	iCell Gene Therapeutics	Multiple myeloma (MM)	Details
Anti-BCMA CAR T-cell therapy (Arcellx)	CART-ddBCMA	Phase Ⅰ	Arcellx	Multiple myeloma (MM)	Details
HPN-217	HPN-217	Phase Ⅱ	Harpoon Therapeutics, Abbvie	Multiple myeloma (MM)	Details
CC-99712	CC-99712	Phase Ⅰ	Celgene	Multiple myeloma (MM)	Details
Human BCMA chimeric antigen receptor autologous T cell（Nanjing Reindeer Medical Technology）	CT103A	Phase Ⅰ	Innovent Biologics, Nanjing IASO Biotherapeutics	Multiple myeloma (MM)	Details
MEDI-2228	MEDI-2228,MEDI 2228,MEDI2228	Phase Ⅰ	MedImmune	Multiple myeloma (MM)	Details
SEA-BCMA	SEA-BCMA; SGN-BCMA	Phase Ⅰ	Seattle Genetics	Multiple myeloma (MM)	Details
bb-21217	bb-21217,bb 21217,bb21217	Phase Ⅰ	bluebird bio, Celgene	Multiple myeloma (MM)	Details
AMG-420	AMG-420; BI-836909	Phase Ⅰ	Micromet, Boehringer Ingelheim, Amgen	Multiple myeloma (MM)	Details
KITE-585	KITE-585,KITE585	Phase Ⅰ	Kite Pharma, National Cancer Institute	Multiple myeloma (MM)	Details
REGN-5459	REGN-5459	Phase Ⅰ	Regeneron Pharmaceutical	Multiple myeloma (MM)	Details
PF-06863135	PF-06863135,PF 06863135	Phase Ⅰ	Pfizer	Multiple myeloma (MM)	Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics)		Phase Ⅰ	iCell Gene Therapeutics	Multiple myeloma (MM), Lymphoma	Details
LCAR-B4822M	LCAR-B4822M,LCAR B4822M,LCARB4822M	Phase Ⅰ	GenScript Biotech Corporation	Multiple myeloma (MM)	Details
CAR-BCMA T cell therapy	CT-053-CARsgen	Phase Ⅰ	CARsgen Therapeutics	Multiple myeloma (MM)	Details
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology)	BCMA-CART	Phase Ⅰ	Shanghai Hrain Biotechnology	Multiple myeloma (MM)	Details
JNJ-64007957	JNJ-7957; JNJ-64007957; JNJ-64007959	Phase Ⅰ	Janssen, Genmab	Multiple myeloma (MM)	Details
AUTO-2	AUTO-2; SUB-96123,AUTO 2; SUB 96123	Phase Ⅱ	Autolus	Multiple myeloma (MM)	Details
CC-93269	CC-93269; EM-901	Phase Ⅰ	Celgene	Multiple myeloma (MM)	Details
ACTR 087/SEA BCMA combination therapy		Phase Ⅰ	Unum Therapeutics, Seattle Genetics	Multiple myeloma (MM)	Details
anti-BCMA CAR T-cell Therapy (Juno Therapeutics)	ET-140; ET140-CAR; JCARH-125; FCARH-143; MCARH-171	Phase Ⅱ	Juno Therapeutics	Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas	Details
ALLO-715	ALLO-715	Phase Ⅰ	Allogene Therapeutics, Cellectis	Multiple myeloma (MM)	Details
BCBM CAR T cell (Pregene)		Phase Not Specified	Pregene, BioCast	Multiple myeloma (MM)	Details